Right Trial: Researchers Are Testing a Non-Surgical Inguinal Hernia Treatment in Humans
What makes this study unusual is the question behind it. The researchers aren’t surgically repairing the hernias. They’re changing a biological process they believe contributes to weakening of the lower abdominal tissue and then using ultrasound to see what happens to the hernia itself.
What is the RIGHT Trial for inguinal hernias?
The RIGHT Trial (NCT07604272) is a Phase 1 clinical trial sponsored by Northwestern University. Its full name is the Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males.
The study is expected to enroll approximately 30 men age 50 and older with symptomatic unilateral inguinal hernias. Participants will receive anti-estrogen therapy for six months while researchers monitor safety and look for changes in the hernias and other outcomes.
| RIGHT Trial Detail | What Researchers Are Doing |
|---|---|
| Study | Reversing InGuinal Hernia Trial (RIGHT) |
| ClinicalTrials.gov ID | NCT07604272 |
| Phase | Phase 1 |
| Estimated enrollment | 30 men |
| Age | 50 years and older |
| Hernia | Symptomatic unilateral inguinal hernia |
| Treatment period | 6 months |
| Key measurement | Change in hernia size measured with ultrasound |
How did researchers get from reversing hernias in mice to a human trial?
The RIGHT Trial didn’t come out of nowhere. It follows years of research into estrogen signaling, fibrosis and changes in the lower abdominal muscles associated with inguinal hernia formation.
A 2022 study identified an estrogen-sensitive population of fibroblasts in a mouse model of inguinal hernia. Fibroblasts are cells involved in producing and maintaining the extracellular matrix and connective tissue. The researchers linked increased estrogen signaling in these cells with fibrosis and weakening of the lower abdominal muscle.
Then came the study that really got my attention.
In research published in 2025, scientists targeted estrogen receptor alpha (ESR1), the receptor involved in this process. When they inhibited ESR1 with the drug fulvestrant, fibrosis decreased, normal muscle architecture was restored, and established hernias in the mice reversed.
You can read the original fulvestrant study on PubMed. The earlier research identifying the estrogen-sensitive fibroblast population is also available in the 2022 JCI Insight study on PubMed.
That’s a very condensed version of the research. I went much deeper into what happened in the mouse study in my previous video:
Watch my breakdown of the fulvestrant inguinal hernia mouse study.

The RIGHT Trial follows research in which blocking estrogen receptor signaling with fulvestrant reversed established hernias in mice.
What are researchers testing in humans?
The RIGHT Trial is testing anti-estrogen therapy in men who already have inguinal hernias.
That’s an important distinction.
This isn’t simply a prevention study asking whether researchers can stop a hernia from developing. These participants already have symptomatic hernias, and researchers are going to measure what happens after estrogen signaling is altered.
The ClinicalTrials.gov record lists fulvestrant as one of the interventions. Fulvestrant is particularly interesting because it is the same drug that reversed established hernias in the mouse study.
The current ClinicalTrials.gov record also lists anastrozole as an intervention, although the study’s brief summary currently refers to letrozole instead. Both anastrozole and letrozole are aromatase inhibitors, but they are different drugs. The registry, therefore, contains a discrepancy as of this writing, and I will update this article if the study record is clarified.
Why use two different approaches?
The treatments target estrogen activity in different ways.
Fulvestrant targets the estrogen receptor itself. In the mouse research, blocking estrogen receptor alpha changed the biological signaling associated with fibroblast activity, fibrosis and deterioration of the lower abdominal muscle.
Aromatase inhibitors reduce estrogen production. Aromatase is an enzyme involved in converting androgens into estrogens.
The broader idea is to find out what happens to an existing human inguinal hernia when this estrogen-related biological pathway is altered.
Are researchers actually trying to shrink the hernias?
Yes. Hernia size is one of the outcomes being measured in the RIGHT Trial.
This may be the most interesting part of the entire study.
The researchers aren’t relying only on whether someone says he feels better. They’re using ultrasound to measure the hernias and look for objective physical changes.
Among the outcomes being tracked are:
- Hernia size
- Hernia-related symptoms and quality of life
- Estradiol and other hormone levels
- Safety and treatment-related side effects
- Bone density
- Imaging-based classification of the hernia
So if a participant feels better but his hernia is physically unchanged, the researchers should be able to distinguish that from a situation where ultrasound shows that the hernia itself has actually become smaller.
That’s a much more interesting question to me than symptom relief alone.

Researchers will use imaging to determine whether anti-estrogen treatment produces measurable changes in the hernias.
Why is the RIGHT Trial studying men over 50?
The age and sex of the participants are directly connected to the biological mechanism being investigated.
The mouse research was designed around hormonal changes associated with aging in men and increased estrogen activity within lower abdominal muscle tissue. Researchers found that estrogen acting through ESR1 in fibroblasts promoted fibrosis and extracellular matrix changes in their model.
The human trial is therefore starting with older men — the population most closely connected to the mechanism the researchers have been studying.
That does not establish estrogen signaling as the explanation for every inguinal hernia. The RIGHT Trial is testing a specific biological mechanism in a specific group of people.
What would make the RIGHT Trial significant?
The RIGHT Trial is a small Phase 1 study, so 30 participants aren’t going to settle the question of non-surgical inguinal hernia treatment.
The first job is to determine whether the approach is safe and feasible enough to continue studying.
But I’ll be especially interested in the ultrasound results.
If researchers alter estrogen signaling and then document measurable changes in existing human inguinal hernias, that would give us a reason to investigate the idea on a much larger scale.
It could also move the hernia conversation further upstream.
Most modern hernia treatment focuses on what to do after the tissue has failed: monitor the hernia or repair the defect surgically.
This research is also asking:
What caused the tissue to weaken, and can any part of that biological process be changed?
I think that’s a question worth pursuing regardless of whether these particular drugs eventually become practical hernia treatments.
Does this mean a non-surgical inguinal hernia treatment is available now?
No. The RIGHT Trial is experimental research, not an established treatment protocol for inguinal hernias.
The trial was registered in 2026 and currently has an estimated completion date in 2028. If the results are promising, larger studies would still be needed to determine how well the approach works and who might benefit.
So this is something worth watching, but it doesn’t give someone with an inguinal hernia a treatment they can use today.
Why this research is especially interesting to me
I’ve followed this research closely because I took a completely different non-surgical path with my own inguinal hernia.
When my hernia was at its worst, it was extremely symptomatic and affected just about everything I did. I started experimenting with exercise, movement, posture, diet, pressure management and other factors that seemed to affect it.
Over time, my situation changed dramatically.
Today I’m completely asymptomatic. I surf, work out and live my life normally without having had hernia surgery.
My experience had nothing to do with fulvestrant or manipulating estrogen signaling, and it doesn’t establish why my own hernia improved.
But it gave me a very good reason to pay attention whenever researchers seriously investigate whether an existing inguinal hernia is more biologically changeable than we’ve traditionally assumed.
If you’re interested in the longer version of my experience, I’ve documented how my inguinal hernia changed without surgery and what I did along the way.
What can you do while this research plays out?
Research moves slowly. If you have an inguinal hernia today, you still have to decide how you’re going to work, exercise and live your life while figuring out what makes sense for your situation.
That’s why I put together my free How to Stay Active With a Hernia guide. It covers the practical strategy that helped me stay active in the early stages while I worked on improving my own situation.
One of the tools that helped me tremendously during that period was a hernia belt. I couldn’t find one that was comfortable enough for surfing, working and exercising, which eventually led me to design my own. If support is something you’re looking for, you can see the Comfort-Truss inguinal hernia belts here.
I also have an older article covering the practical ways I used to manage my inguinal hernia without surgery. That article is about day-to-day management and my personal approach; this page is specifically about the new human research.
Frequently asked questions about the RIGHT Trial
What does RIGHT stand for?
RIGHT stands for Reversing InGuinal Hernia Trial. The official study title is “Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males.”
Is the RIGHT Trial testing fulvestrant in humans?
Yes. Fulvestrant is one of the anti-estrogen interventions listed in the trial. This is the same drug researchers used to reverse established inguinal hernias in their mouse model.
Will the trial measure whether the hernias actually get smaller?
Yes. Researchers are using imaging to measure changes in hernia size. This allows them to look for objective physical changes rather than relying only on pain or symptom reports.
Can I use fulvestrant or anastrozole to treat my inguinal hernia now?
The RIGHT Trial is experimental. Anti-estrogen drugs are not currently an established treatment for inguinal hernias, and this Phase 1 trial is being conducted specifically to investigate safety, feasibility and biological effects.
When will we know the results?
ClinicalTrials.gov currently lists June 2028 as the estimated primary completion and study completion date. Results could take additional time to analyze and publish.
Where this research goes next
We don’t know whether the dramatic results seen in mice will translate to people.
That’s exactly why this trial matters.
The progression is now clear: researchers identified an estrogen-sensitive biological mechanism associated with lower abdominal muscle fibrosis, blocked that pathway and reversed established hernias in mice, and have now moved into a human trial that will measure what happens to existing inguinal hernias.
I’ll continue following the RIGHT Trial as it progresses and update this site when meaningful results become available.
The question I’m most interested in is still remarkably simple:
If researchers change the biology of the tissue, will the human hernia itself change?
Now we’re finally going to start finding out.



















